Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone + Prednisone vs Darolutamide in Advanced Prostate Cancer
NCT06173362Phase 2Recruiting
- Sponsor
- University of California, Davis
- Start
- Nov 2023
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of abiraterone, darolutamide in prostate cancer (PCa), sponsored by University of California, Davis. Started Nov 2023; status: recruiting.
02
Drugs
abirateronedarolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06173362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06173362.